Potentials of drug therapy for metastatic/recurrent cervical cancer
- Authors: Ulrikh E.A.1,2, Semiglazova T.Y.1, Khalimbekova D.I1, Smirnova O.A1, Ulrikh D.G2, Urmancheeva A.F1
-
Affiliations:
- Northwestern State Medical University n.a. I.I. Mechnikov
- St. Petersburg State Pediatric Medical University
- Issue: No 12 (2018)
- Pages: 29-32
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/295792
- DOI: https://doi.org/10.18565/pharmateca.2018.12.29-32
- ID: 295792
Cite item
Abstract
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
About the authors
Elena A. Ulrikh
Northwestern State Medical University n.a. I.I. Mechnikov; St. Petersburg State Pediatric Medical University
Email: rectorat@szgmu.ru
MD, Professor, Prof. at the Department
T. Yu Semiglazova
Northwestern State Medical University n.a. I.I. Mechnikov
D. I Khalimbekova
Northwestern State Medical University n.a. I.I. Mechnikov
O. A Smirnova
Northwestern State Medical University n.a. I.I. Mechnikov
D. G Ulrikh
St. Petersburg State Pediatric Medical University
A. F Urmancheeva
Northwestern State Medical University n.a. I.I. Mechnikov
References
- Bonomi P., Blessing J.A., Stehman F.B., et al. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J. Clin Oncol. 1985; 3:1079-85.
- Monk B.J., Sill M.W., McMeekin D.S., et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J. Clin Oncol. 2009;27:4649-55. Doi: 10.1200/ JCO.2009.21.8909.
- Kitagawa R., Katsumata N., Shibata T., et al. A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVB, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCOG0505) J. Clin Oncol. 2012;(Suppl):abstr 5006.
- Практические рекомендации по лекарственному лечению злокачественных опухолей. Практические рекомендации по поддерживающей терапии в онкологии (RUSSCO). Под ред. В.М. Моисеенко. М., 2017; спецвыпуск 7(3):58-167.
- Monk B.J., Sill M.W., Burger R.A., et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J. Clin Oncol. 2009;27:1069-74. doi: 10.1200/JCO.2008.18.9043.
- Zighelboim I., Wright J.D., Feng Gaoc F. et al. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol 2013;130(1):64-8. Doi: 10.1016/j. ygyno.2013.04.009.
- Tewari K.S., Sill M.W., Penson R.T., et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240) ational Cancer Institute. Lancet. 2017;390(10103):1654-63. doi: 10.1016/S0140-6736(17)31607-0.
- Хохлова. С.В. Место бевацизумаба в лечении больных раком яичников и раком шейки матки. Современная онкология. 2017;1:34-41.
- Okawa T., Niibe H., Arai T., et al. Effect of LC9018 combined with radiation therapy on carcinoma of the uterine cervix. A phase III, multicenter, randomized, controlled study. Cancer. 1993;72:1949-54.
- Fujiwara K., Ohashi Y., Ochiai K., et al. Phase III placebo controlled double blind randomized trial of radiation therapy for stage 2B-4A cervical cancer with immunomodulator Z-100: JGOG-DT101 study. J. Clin Oncol. 2013; (Suppl; abstr 5506).
- Gunn G.R., Zubair A., Peters C., et al. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol. 2001;167:6471-79.
- Kaufmann A.M., Stern P.L., Rankin E.M., et al. Safety andimmunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res. 2002;8:3676-85.
- Ressing M.E., van Driel W.J., Brandt R.M., et al. Detection of T. helper responses, but not of human papillomavirus- specific cytotoxic T. lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J. Immunother. 2000;23:255-66.
- Kenter G.G., Welters M.J., Valentijn A.R., et al. Phase I. immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin CancerRes. 2008;14:169-77. doi: 10.1158/1078-0432.CCR-07-1881.
- Welters M.J., Kenter G.G., Piersma S.J., et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res. 2008;14:178-87. doi: 10.1158/1078-0432. CCR-07-1880.
- Ferrara A., Nonn M., Sehr P., et al. Dendritic cell-base tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J. Cancer Res Clin Oncol. 2003;129:521-30.
Supplementary files
![](/img/style/loading.gif)